GLPG Quote, Financials, Valuation and Earnings

MDxHealth SA has a net margin of -84.26% compared to Galapagos NV's net margin of -47.99%. Galapagos NV's return on equity of 7.25% beat MDxHealth SA's return on equity of -650.14%.

Galapagos NV has a consensus price target of $29.66, signalling upside risk potential of 15.65%. On the other hand MDxHealth SA has an analysts' consensus of $6.0400 which suggests that it could grow by 205.05%. Given that MDxHealth SA has higher upside potential than Galapagos NV, analysts believe MDxHealth SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.214, which suggesting that the stock is 78.61% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -384,676.085, suggesting its less volatile than the S&P 500 by 38467708.461%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $65.8M, which are larger than MDxHealth SA quarterly revenues of $23.3M. Galapagos NV's net income of -$55.5M is lower than MDxHealth SA's net income of -$11.2M. Notably, Galapagos NV's price-to-earnings ratio is 7.62x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.98x versus 0.76x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Mithra Pharmaceuticals SA has a net margin of -84.26% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 7.25% beat Mithra Pharmaceuticals SA's return on equity of --.

Galapagos NV has a consensus price target of $29.66, signalling upside risk potential of 15.65%. On the other hand Mithra Pharmaceuticals SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Mithra Pharmaceuticals SA, analysts believe Galapagos NV is more attractive than Mithra Pharmaceuticals SA.

Galapagos NV has a beta of 0.214, which suggesting that the stock is 78.61% less volatile than S&P 500. In comparison Mithra Pharmaceuticals SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mithra Pharmaceuticals SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Mithra Pharmaceuticals SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $65.8M, which are larger than Mithra Pharmaceuticals SA quarterly revenues of --. Galapagos NV's net income of -$55.5M is higher than Mithra Pharmaceuticals SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 7.62x while Mithra Pharmaceuticals SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.98x versus -- for Mithra Pharmaceuticals SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -84.26% compared to Galapagos NV's net margin of -1347.39%. Galapagos NV's return on equity of 7.25% beat Nyxoah SA's return on equity of -51.1%.

Galapagos NV has a consensus price target of $29.66, signalling upside risk potential of 15.65%. On the other hand Nyxoah SA has an analysts' consensus of -- which suggests that it could grow by 69.64%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.214, which suggesting that the stock is 78.61% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $65.8M, which are larger than Nyxoah SA quarterly revenues of $1.4M. Galapagos NV's net income of -$55.5M is lower than Nyxoah SA's net income of -$18.8M. Notably, Galapagos NV's price-to-earnings ratio is 7.62x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.98x versus 51.34x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -84.26% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 7.25% beat UCB SA's return on equity of 2.64%.

Galapagos NV has a consensus price target of $29.66, signalling upside risk potential of 15.65%. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

Galapagos NV has a beta of 0.214, which suggesting that the stock is 78.61% less volatile than S&P 500. In comparison UCB SA has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.64%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.73% to investors and pays a quarterly dividend of $0.72 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 73.47% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galapagos NV quarterly revenues are $65.8M, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of -$55.5M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 7.62x while UCB SA's PE ratio is 150.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.98x versus 6.64x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.